China SXT Pharmaceuticals, Inc.
SXTC
$1.50
$0.021.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.85% | -7.85% | -11.73% | -11.73% | 29.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.85% | -7.85% | -11.73% | -11.73% | 29.55% |
| Cost of Revenue | -6.14% | -6.14% | 6.70% | 6.70% | 69.45% |
| Gross Profit | -12.42% | -12.42% | -53.26% | -53.26% | -21.09% |
| SG&A Expenses | 132.54% | 132.54% | -91.98% | -91.98% | -257.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.12% | 147.12% | -85.73% | -85.73% | -228.68% |
| Operating Income | -128.14% | -128.14% | 93.17% | 93.17% | 276.67% |
| Income Before Tax | -137.91% | -137.91% | 91.72% | 91.72% | 248.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -137.91% | -137.91% | 91.72% | 91.72% | 248.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.91% | -137.91% | 91.72% | 91.72% | 248.59% |
| EBIT | -128.14% | -128.14% | 93.17% | 93.17% | 276.67% |
| EBITDA | -127.57% | -127.57% | 93.84% | 93.84% | 285.44% |
| EPS Basic | -102.39% | -102.39% | 98.72% | 98.72% | 152.00% |
| Normalized Basic EPS | -102.25% | -102.25% | 98.72% | 98.72% | 160.06% |
| EPS Diluted | -102.39% | -102.39% | 98.72% | 98.72% | 152.00% |
| Normalized Diluted EPS | -102.25% | -102.25% | 98.72% | 98.72% | 160.06% |
| Average Basic Shares Outstanding | 1,484.11% | 1,484.11% | 544.18% | 544.18% | 185.56% |
| Average Diluted Shares Outstanding | 1,484.11% | 1,484.11% | 544.18% | 544.18% | 185.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |